D-Wave Quantum Is Skyrocketing Today -- Is the Stock a Buy Right Now?

D-Wave Quantum shares jumped 17.2% after TD Cowen named it one of the top three beneficiaries of the U.S. government's quantum computing investment initiative, alongside Rigetti Computing and GlobalFoundries. The company also disclosed a letter of intent for $100 million in CHIPS Act funding over three years, in exchange for issuing new stock to the Department of Commerce. The deal is positive for validation and growth prospects, but it implies shareholder dilution and leaves the stock highly speculative at roughly 263 times expected sales.

Analysis

This is less a fundamental re-rating than a credibility event. The market is effectively pricing a government-backed option on quantum commercialization, but the structure matters: dilution arrives now while operating leverage, if any, arrives years later. That asymmetry tends to create a reflexive squeeze in the first leg, then a valuation hangover once investors realize the cash infusion does not solve product-market fit or meaningful revenue scale.

The second-order winner may be the adjacent names with cleaner industrial narratives. RGTIW can keep outperforming on the same policy flow, while GFS has a more actionable read-through because it offers semiconductor manufacturing leverage without needing quantum adoption to work on a multi-year timeline. By contrast, the move is not obviously positive for NVDA or INTC despite being cited in the thematic basket; the real capital allocation implication is that Washington is signaling where it wants strategic capacity, not where it expects near-term earnings.

The main risk is that the stock is now trading on policy optionality rather than discounted cash flow, which makes it fragile to any delay, amendment, or perceived dilution overhang. If the funding cadence slips by even one quarter, momentum holders may de-risk quickly because the thesis is sentiment-driven and crowded. The more important time horizon is months, not days: the trade works as long as the market keeps treating government validation as a proxy for inevitability, but that premium can compress sharply once lock-up, share issuance, and execution questions dominate.

The contrarian angle is that this may be a better shorting candidate on strength than a buy-and-hold. The market is extrapolating a category winner from a subsidy program, but history says public-sector support often enriches suppliers and later-stage enablers more reliably than the most speculative recipient. If the stock gets another 15-25% from here without new commercial data, the risk/reward tilts toward fade rather than chase.

Key Decisions for Investors

• Fade strength in QBTS with a tactical short or put spread over the next 2-6 weeks if the stock gaps higher again; target a retracement of part of the policy premium, with dilution/execution risk as the catalyst
• Relative-value long RGTIW / short QBTS for 1-3 months to express the view that the market is overpaying for the cleanest policy beta while underweighting the more directly levered beneficiary
• Small long GFS versus QBTS as a lower-volatility way to own the same policy theme; use a 3-6 month horizon and size for multiple expansion, not quantum commercialization
• If already long QBTS, sell upside calls against the position into elevated implied volatility to monetize the sentiment spike while capping further upside participation
• Avoid chasing NVDA/INTC on this headline alone; wait for evidence of actual procurement or capex spillover before assuming material earnings impact